LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naive prostate cancer (mHNPC) | |
Feyerabend, S.; Tran, N.; Fein, L.; Matsubara, N.; Rodriguez Antolin, A.; Alekseev, B.; Ozguroglu, M.; Ye, D.; Protheroe, A.; De Porre, P. | |
2017 | |
卷号 | 40 |
会议录 | ONCOLOGY RESEARCH AND TREATMENT
![]() |
语种 | 英语 |
URL标识 | 查看原文 |
ISSN号 | 2296-5270 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3619427 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Feyerabend, S.,Tran, N.,Fein, L.,et al. LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naive prostate cancer (mHNPC)[C]. 见:. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论